Results 51 to 60 of about 46,198 (239)

Clinical Model‐Informed Precision Dosing Consult Service for Accelerating Personalized Medication in Pediatric Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Traditional dosing strategies often rely on a “one‐size‐fits‐all” paradigm, assuming an “average” patient with typical demographic and pharmacological characteristics. In reality, this often overlooks existing between‐patient variability and can lead to suboptimal drug exposure or toxicity. This issue is especially pronounced in pediatric patients, who
Zachary L. Taylor   +12 more
wiley   +1 more source

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease

open access: yes, 2019
Objective To evaluate the induction of DNA damage in peripheral blood mononuclear cells of patients with sickle cell disease, SS and SC genotypes, treated with hydroxyurea.
Cibele Velloso-Rodrigues (7368221)   +6 more
core   +1 more source

Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: A qualitative study [PDF]

open access: yes, 2020
Hydroxyurea is an efficacious treatment for sickle cell disease (SCD), but adoption is low among individuals with SCD. The objective of this study was to examine barriers to patients' adherence to hydroxyurea use regimens by using the intentional and ...
King, Allison   +32 more
core   +1 more source

Treatment comparison of hydroxyurea versus ruxolitinib in essential thrombocythaemia: A matched‐cohort analysis

open access: yeseJHaem
Hydroxyurea is the preferred first‐line cytoreductive treatment for high‐risk essential thrombocythaemia (ET), but many patients are intolerant or refractory to hydroxyurea. Ruxolitinib has been shown to improve symptoms in patients with ET.
Michael R. Grunwald   +8 more
doaj   +1 more source

The Cell Killing Mechanisms of Hydroxyurea

open access: yes, 2016
Hydroxyurea is a well-established inhibitor of ribonucleotide reductase that has a long history of scientific interest and clinical use for the treatment of neoplastic and non-neoplastic diseases.
Yong-Jie Xu, Amanpreet Singh
core   +1 more source

HOPE Kids 2: Phase 3, Randomized Trial of Voxelotor in Children With SCD and Conditional Cerebral Blood Flow Velocities. [PDF]

open access: yesAm J Hematol
ABSTRACT Children with SCD have elevated stroke risk, correlated with cerebral blood flow velocity (CBFV). HOPE Kids 2 was a phase 3, multicenter, double‐blind, placebo‐controlled trial evaluating the effect of voxelotor on CBFV. Participants aged 2 to < 15 years with SCD (HbSS/HbSβ0) and conditional CBFV (170 to < 200 cm/s) were randomized 1:1 to ...
Bello-Manga H   +25 more
europepmc   +2 more sources

Circulating monocyte partitioning and its alteration in hematological chronic neoplasms

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Circulating monocyte partitioning refers to the relative quantification of the three main monocyte subsets in the peripheral blood, namely classical (cMo), intermediate (iMo), and non‐classical (ncMo) monocytes, as assessed by flow cytometry, a new nomenclature described 15 years ago.
Sihem Tarfi   +4 more
wiley   +1 more source

Coexistence of immunophenotypically normal and aberrant mast cells in patients with clonal mast cell diseases associates with more indolent subtypes and less severe disease characteristics

open access: yesCytometry Part B: Clinical Cytometry, EarlyView.
Abstract Aberrant antigen expression on mast cells (MCs) is one of the most accurate diagnostic markers for clonal MC diseases (CMCD). Although the coexistence of normal and pathologic MCs is frequently seen, the disease characteristics associated with it have been minimally investigated.
Abdulrazzaq Alheraky   +6 more
wiley   +1 more source

Replication Rapidly Recovers and Continues in the Presence of Hydroxyurea in Escherichia coli [PDF]

open access: yes, 2018
In both prokaryotes and eukaryotes, hydroxyurea is suggested to inhibit DNA replication by inactivating ribonucleotide reductase and depleting deoxyribonucleoside triphosphate pools.
Hackert, Brandy J.   +11 more
core   +1 more source

Impact of Xmn1 polymorphism on hydroxyurea therapy in children with HbE-β non-transfusion dependent thalassemia: a cohort study [PDF]

open access: yesClinical and Experimental Pediatrics
Background Fetal hemoglobin (HbF) inducers, among which hydroxyurea is the most extensively used, have shifted the paradigm toward the treatment of non–transfusion-dependent thalassemia (NTDT).
Saheli Roy   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy